Stamelou M - Search Results

1

From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link.

Respondek G, Höglinger GU, Stamelou M. Respondek G, et al. Among authors: stamelou m. Mov Disord. 2015 Dec;30(14):1871-2. doi: 10.1002/mds.26464. Epub 2015 Nov 14. Mov Disord. 2015. PMID: 26566709 Review. No abstract available.

2

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.

Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, Krisp A, Menke T, Schade-Brittinger C, Oertel WH, Höglinger GU. Stamelou M, et al. Mov Disord. 2008 May 15;23(7):942-949. doi: 10.1002/mds.22023. Mov Disord. 2008. PMID: 18464278 Clinical Trial.

3

Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid stenosis and changes upon treatment.

Hattingen E, Lanfermann H, Menon S, Neumann-Haefelin T, de Rochement RD, Stamelou M, Höglinger GU, Magerkurth J, Pilatus U. Hattingen E, et al. Among authors: stamelou m. MAGMA. 2009 Feb;22(1):43-52. doi: 10.1007/s10334-008-0148-9. Epub 2008 Oct 15. MAGMA. 2009. PMID: 18855032 Clinical Trial.

4

In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy.

Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, Knake S, Ruberg M, Schade-Brittinger C, Oertel WH, Höglinger GU. Stamelou M, et al. J Cereb Blood Flow Metab. 2009 Apr;29(4):861-70. doi: 10.1038/jcbfm.2009.2. Epub 2009 Feb 4. J Cereb Blood Flow Metab. 2009. PMID: 19190655

5

Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.

Stamelou M, Matusch A, Elmenhorst D, Hurlemann R, Eggert KM, Zilles K, Oertel WH, Höglinger GU, Bauer A. Stamelou M, et al. Mov Disord. 2009 Jun 15;24(8):1170-5. doi: 10.1002/mds.22533. Mov Disord. 2009. PMID: 19353726

6

In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS.

Knake S, Belke M, Menzler K, Pilatus U, Eggert KM, Oertel WH, Stamelou M, Höglinger GU. Knake S, et al. Among authors: stamelou m. Mov Disord. 2010 Jul 15;25(9):1232-8. doi: 10.1002/mds.23054. Mov Disord. 2010. PMID: 20222139

7

Rational therapeutic approaches to progressive supranuclear palsy.

Stamelou M, de Silva R, Arias-Carrión O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU. Stamelou M, et al. Brain. 2010 Jun;133(Pt 6):1578-90. doi: 10.1093/brain/awq115. Epub 2010 May 14. Brain. 2010. PMID: 20472654 Review.

8

Magnetic resonance imaging in progressive supranuclear palsy.

Stamelou M, Knake S, Oertel WH, Höglinger GU. Stamelou M, et al. J Neurol. 2011 Apr;258(4):549-58. doi: 10.1007/s00415-010-5865-0. Epub 2010 Dec 22. J Neurol. 2011. PMID: 21181185

9

Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes.

Stamelou M, Christ H, Reuss A, Oertel W, Höglinger G. Stamelou M, et al. Mov Disord. 2011 Apr;26(5):901-5. doi: 10.1002/mds.23587. Epub 2011 Mar 7. Mov Disord. 2011. PMID: 21384428

10

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.

Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE. Winter Y, et al. Among authors: stamelou m. J Neurol. 2011 Oct;258(10):1827-34. doi: 10.1007/s00415-011-6028-7. Epub 2011 Apr 10. J Neurol. 2011. PMID: 21479850

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters